Literature DB >> 22006328

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

Emily G Farrow1, Xijie Yu, Lelia J Summers, Siobhan I Davis, James C Fleet, Matthew R Allen, Alexander G Robling, Keith R Stayrook, Victoria Jideonwo, Martin J Magers, Holly J Garringer, Ruben Vidal, Rebecca J Chan, Charles B Goodwin, Siu L Hui, Munro Peacock, Kenneth E White.   

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR) is unique among the disorders involving Fibroblast growth factor 23 (FGF23) because individuals with R176Q/W and R179Q/W mutations in the FGF23 (176)RXXR(179)/S(180) proteolytic cleavage motif can cycle from unaffected status to delayed onset of disease. This onset may occur in physiological states associated with iron deficiency, including puberty and pregnancy. To test the role of iron status in development of the ADHR phenotype, WT and R176Q-Fgf23 knock-in (ADHR) mice were placed on control or low-iron diets. Both the WT and ADHR mice receiving low-iron diet had significantly elevated bone Fgf23 mRNA. WT mice on a low-iron diet maintained normal serum intact Fgf23 and phosphate metabolism, with elevated serum C-terminal Fgf23 fragments. In contrast, the ADHR mice on the low-iron diet had elevated intact and C-terminal Fgf23 with hypophosphatemic osteomalacia. We used in vitro iron chelation to isolate the effects of iron deficiency on Fgf23 expression. We found that iron chelation in vitro resulted in a significant increase in Fgf23 mRNA that was dependent upon Mapk. Thus, unlike other syndromes of elevated FGF23, our findings support the concept that late-onset ADHR is the product of gene-environment interactions whereby the combined presence of an Fgf23-stabilizing mutation and iron deficiency can lead to ADHR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22006328      PMCID: PMC3219119          DOI: 10.1073/pnas.1110905108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

3.  Familial hypophosphatemic rickets showing autosomal dominant inheritance.

Authors:  J W Bianchine; A A Stambler; H E Harrison
Journal:  Birth Defects Orig Artic Ser       Date:  1971-05

4.  Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets.

Authors:  P J Marie; F H Glorieux
Journal:  Calcif Tissue Int       Date:  1983-07       Impact factor: 4.333

5.  Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors.

Authors:  Christina Warnecke; Wanja Griethe; Alexander Weidemann; Jan Steffen Jürgensen; Carsten Willam; Sebastian Bachmann; Yuri Ivashchenko; Ingrid Wagner; Ulrich Frei; Michael Wiesener; Kai-Uwe Eckardt
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

6.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

8.  Effects of dietary iron deficiency on muscle fiber characteristics and whole-body distribution of hemoglobin in mice.

Authors:  Y Ohira; S L Gill
Journal:  J Nutr       Date:  1983-09       Impact factor: 4.798

9.  Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death.

Authors:  Beom-Su Kim; Kwon-Ha Yoon; Hyun-Mee Oh; Eun-Young Choi; Sang-Wook Kim; Weon-Cheol Han; Eun-A Kim; Suck-Chei Choi; Tae-Hyeon Kim; Ki-Jung Yun; Eun-Cheol Kim; June-Hyung Lyou; Yong-Ho Nah; Hun-Taeg Chung; Young-Nam Cha; Chang-Duk Jun
Journal:  Cell Immunol       Date:  2002-12       Impact factor: 4.868

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  165 in total

1.  Randomized trial of intravenous iron-induced hypophosphatemia.

Authors:  Myles Wolf; Glenn M Chertow; Iain C Macdougall; Robert Kaper; Julie Krop; William Strauss
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

3.  C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.

Authors:  Michele F Eisenga; Marco van Londen; David E Leaf; Ilja M Nolte; Gerjan Navis; Stephan J L Bakker; Martin H de Borst; Carlo A J M Gaillard
Journal:  J Am Soc Nephrol       Date:  2017-08-03       Impact factor: 10.121

Review 4.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

5.  The Authors Reply.

Authors:  Katherine Wesseling-Perry
Journal:  Kidney Int       Date:  2015-09       Impact factor: 10.612

6.  FGF23 in chronic kidney disease: are we lost in translation?

Authors:  Justine Bacchetta
Journal:  Bonekey Rep       Date:  2016-01-06

7.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

8.  Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.

Authors:  Erik A Imel; Amie K Gray; Leah R Padgett; Michael J Econs
Journal:  Bone       Date:  2013-12-08       Impact factor: 4.398

Review 9.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

Review 10.  Fibroblast growth factor 23 and acute kidney injury.

Authors:  Javier A Neyra; Orson W Moe; Ming Chang Hu
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.